Citadel Advisors
BLRX

Citadel Advisors’s BioLineRX BLRX Stock Holding History

Citadel Advisors’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,000
Closed -$34.2K – 13014
2025
Q4 		$34.2K Buy
+12,000
New +$41.5K ﹤0.01% 12183
2025
Q3 		– Sell
-12,200
Closed -$55.8K – 12787
2025
Q2 		$55.8K Buy
+12,200
New +$45.1K ﹤0.01% 11719
2025
Q1 		– Sell
-128
Closed -$1.08K – 14506
2024
Q4 		$1.08K Sell
128
-30
-19% -$443 ﹤0.01% 14226
2024
Q3 		$3.38K Sell
158
-122
-44% -$3.35K ﹤0.01% 13661
2024
Q2 		$6.34K Sell
280
-25
-8% -$671 ﹤0.01% 13338
2024
Q1 		$13.7K Buy
305
+195
+177% +$9.78K ﹤0.01% 13286
2023
Q4 		$6.91K Buy
110
+5
+5% +$309 ﹤0.01% 13326
2023
Q3 		$7.64K Buy
105
+102
+3,400% +$6.85K ﹤0.01% 13247
2023
Q2 		$160 Buy
+3
New +$166 ﹤0.01% 14203
2022
Q1 		– Sell
-593
Closed -$48K – 13595
2021
Q4 		$48K Sell
593
-1,472
-71% -$153K ﹤0.01% 13267
2021
Q3 		$226K Buy
2,065
+1,255
+155% +$149K ﹤0.01% 11707
2021
Q2 		$91K Buy
+810
New +$95.2K ﹤0.01% 12988

Other funds holding BLRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NRG
Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citadel Advisors's BLRX Position: Q1 2026 in Review

Citadel Advisors sold out of BioLineRX (BLRX) in Q1 2026, closing a stake of 36,651 shares — an estimated $104K sold.

Citadel Advisors first reported a position in BLRX in Q1 2014 and held it in 20 quarters. The position peaked at $451K in Q3 2021. 13 funds tracked by Wall St. Rank hold BLRX as of Q1 2026.

  • Citadel Advisors reported no remaining BioLineRX position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 36,651 BioLineRX shares in Q1 2026, an estimated $104K.
  • Citadel Advisors first reported a position in BioLineRX in Q1 2014 and held it in 20 quarters.
  • Citadel Advisors's BioLineRX position peaked at $451K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held BioLineRX as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.